All manuscripts
Publications CAR T Cells G-Rex®6 Well Plate

Assessment of anti-CD20 antibody pre-treatment for augmentation of CAR-T cell therapy in SIV-infected rhesus macaques

Published Journal Frontiers in Immunology

Share
17 pages Assessment of anti-CD20 antibody pre-treatment for augmentation of CAR-T cell therapy in SIV-infected rhesus macaques — Frontiers in Immunology, 2023

Overview

This study evaluates anti-CD20 pre-treatment for enhancing SIV-specific CAR-T cell therapy in macaques. CAR-T cells were manufactured using G-Rex® 6-well plates for expansion. While anti-CD20 treatment increased initial CAR-T expansion, the cells failed to persist long-term, and viral loads were not significantly affected.

What this paper found

Anti-CD20 pre-treatment of SIV-infected rhesus macaques before CD4-MBL-CAR/CXCR5 T-cell infusion was associated with greater follicular CAR-T expansion but did not improve persistence or lower viral load. Animals on antiretroviral therapy received 7 mg/kg anti-CD20 seven days before infusion, which depleted blood CD20+ cells almost completely and lymph node CD20+ cells partially. Follicular CAR-T cells rose a median 15.2-fold between days 2 and 6 in depleted animals versus 8.1-fold in non-depleted animals, and nearly all were Ki67+. Depleted animals showed prolonged elevated IL-6, one animal developed cytokine release syndrome and was euthanized at day 2, and CAR-T cells disappeared rapidly.

Note: Small cohort; the authors note that the number of depleted/CAR-T animals was too small to expect statistical significance in the comparison of fold expansion.

Overall, a single low dose anti-CD20 pre-treatment may effectively enhance the proliferation and accumulation of CAR-T cells at viral reservoir sites, but this treatment requires inclusion of IL-6 inhibitors to prevent CRS — Mary S. Pampusch, Emily N. Sevcik, Zoe E. Quinn, Brianna C. Davey, James M. Berg, Ian Gorrell-Brown, Hadia M. Abdelaal, Eva G. Rakasz, Aaron Rendahl, Pamela J. Skinner, Frontiers in Immunology

Study details

Authors
Mary S. Pampusch, Emily N. Sevcik, Zoe E. Quinn, Brianna C. Davey, James M. Berg, Ian Gorrell-Brown, Hadia M. Abdelaal, Eva G. Rakasz, Aaron Rendahl, Pamela J. Skinner
Institution
Department of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, Minnesota, United States · Wisconsin National Primate Research Center, University of Wisconsin, Madison, Wisconsin, United States
Journal
Frontiers in Immunology
Year
2023
PMID / PMC
PMID: 36825014 · PMC
G-Rex® model(s)
G-Rex®6 Well Plate
Cell type(s)
CAR T Cells
Application area
Infectious disease
Study phase
Preclinical

How G-Rex® was used

After retroviral transduction of autologous rhesus PBMCs, the CD4-MBL-CAR/CXCR5 T cells were moved into G-Rex® 6 well plates and expanded for 4 days in medium containing 50 U/ml IL-2. Cells were then collected, washed and resuspended at 2 × 10^7 cells/mL in PBS with 10% autologous serum for intravenous infusion at doses of 0.1 to 2.3 × 10^8 cells/kg.

Explore related

Full citation

Pampusch MS, Sevcik EN, Quinn ZE, et al. Assessment of anti-CD20 antibody pre-treatment for augmentation of CAR-T cell therapy in SIV-infected rhesus macaques. Front Immunol. 2023;14:1101446.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →